Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-SARS-CoV-2 convalescent plasma (Centro Médico ABC)
- Development stage
- Discontinued
- Lead developer
- OneBlood
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Anti-SARS-CoV-2 convalescent plasma is a biologic, blood-derived passive immunotherapy consisting of plasma collected from individuals who have recovered from COVID-19. This plasma contains polyclonal antibodies, specifically neutralizing IgG antibodies, directed against the SARS-CoV-2 virus. The therapy aims to provide immediate, passive immunity to patients with active COVID-19 infections by neutralizing the virus and preventing further cellular entry. It was investigated by Centro Medico ABC in Mexico for the treatment of severe and critical COVID-19 pneumonia in hospitalized patients. However, clinical trials, including NCT04432103, were terminated or showed limited benefit in severe cases, leading to a shift in focus toward other treatments.
- Other names
- COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaconvalescent plasmaCCP
02
Targets
E (Tick-borne encephalitis virus envelope protein)N (Nucleocapsid protein)M protein (SARS-CoV-2 membrane protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on anti-SARS-CoV-2 convalescent plasma (Centro Médico ABC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-SARS-CoV-2 convalescent plasma (Centro Médico ABC).